8-K - MGRX - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 29, 2024

MANGOCEUTICALS,

INC.

(Exactname of registrant as specified in its charter)

Texas	001-41615	87-3841292
(State or other jurisdiction<br><br> <br>of incorporation)	(Commission<br><br> <br>File Number)	(IRS Employer<br><br> <br>Identification No.)
15110 N. Dallas Parkway, Suite 600<br><br> <br>Dallas, Texas	75248
---	---
(Address of principal executive offices)	(Zip Code)

Registrant’stelephone number, including area code: (214) 242-9619

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common<br> Stock, $0.0001 Par Value Per Share	MGRX	The<br> Nasdaq Stock Market LLC<br><br> <br>(Nasdaq<br> Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed in the Current Report on Form 8-K, filed by Mangoceuticals, Inc., a Texas corporation (the “Company”, “we” and “us”) with the Securities and Exchange Commission (the “Commission” or the “SEC”) on November 1, 2023, on October 30, 2023, the Company received written notice (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days. Based on the closing bid price of the Company’s common stock for the thirty (30) consecutive business days from September 15, 2023 to October 27, 2023, the Company no longer met the minimum bid price requirement.

The Notification Letter stated that the Company had 180 calendar days or until April 29, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days (the “Minimum Bid Price Requirement”). The Notification Letter also stated that if the Company does not regain compliance by April 29, 2024, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market initial listing criteria (except for the bid price requirement) and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

As previously disclosed in the Current Report on Form 8-K, filed by the Company with the Commission on November 7, 2023, on November 3, 2023, the Company received a letter from Nasdaq notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the Company reported stockholders’ equity of $1,354,821, which is below the minimum stockholders’ equity required for continued listing pursuant to the Rule. Additionally, the Company did not meet the alternative Nasdaq continued listing standards under Nasdaq Listing Rules.

As described in the Current Report on Form 8-K filed by the Company with the Commission on April 25, 2024, as a result of certain transactions described in such Current Report on Form 8-K, the Company believes it has regained compliance with the Rule because it believes that its stockholders’ equity exceeds $2.5 million and that it also satisfies the minimum $5 million equity requirement for initial listing on The Nasdaq Capital Market.

On April 25, 2024, the Company submitted a request to Nasdaq for an additional 180-day extension to regain compliance with the Minimum Bid Price Requirement.

On April 30, 2024, the Company received a letter from Nasdaq advising that based on the April 25, 2024 Current Report on Form 8-K, Nasdaq has determined that the Company complies with the Rule. However, Nasdaq also advised that if the Company fails to evidence compliance with the Rule upon filing its next periodic report it may be subject to delisting. At that time, Nasdaq will provide written notification to the Company, which may then appeal Nasdaq’s determination to a Hearings Panel.

Separately, on April 30, 2024, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to October 24, 2024, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A).

The Company will continue to monitor the closing bid price of its common stock and will, if necessary, implement a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. The stockholders of the Company, at the March 25, 2024, special meeting of stockholders previously approved an amendment to our Certificate of Formation, as amended, to effect a reverse stock split of our issued and outstanding shares of our common stock, by a ratio of between one-for-two to one-for-fifty, inclusive, with the exact ratio to be set at a whole number to be determined by our Board of Directors or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and prior to March 25, 2025.

If the Company does not regain compliance within the allotted compliance period, and/or if the Company does not demonstrate compliance with the Rule as of the filing of its next periodic report, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during this 180-day extension.

Item3.03 Material Modification to Rights of Security Holders.

The

information contained in Item 5.03 relating to the Certificate of Correction (as discussed in Item 5.03), below, is incorporated in this Item 3.03 by reference.

Item5.03 Amendments to Designation of Incorporation or Bylaws; Change in Fiscal Year.

Certificateof Correction

As previously disclosed in the Current Report on Form 8-K filed by the Company with the Commission on April 25, 2024, on April 19, 2024, the Company submitted for filing to the Secretary of State of Texas, a Certificate of Designations of Mangoceuticals, Inc. Establishing the Designations, Preferences, Limitations and Relative Rights of Its 6% Series C Convertible Cumulative Preferred Stock (the “Series C Designation”), which was filed with the Secretary of State of Texas on April 23, 2024, effective as of April 19, 2024 and which designated 6,250,000 shares of Series C Preferred Stock.

Subsequent to the filing of the Series C Designation, the Company became aware of certain errors associated with section cross references and numbering as set forth therein. As a result, on April 29, 2024, the Company filed a Certificate of Correction with the Secretary of State of Texas correcting the prior Series C Designation, which was accepted by Texas effective as of the same date, but effective as of the original date of filing of the Series C Designation for all purposes.

The foregoing description of the Certificate of Correction and its contents are qualified in its entirety by the full text of the Certificate of Correction, which is filed as Exhibit 3.1 to, and incorporated by reference in, this report.

The rights and preferences of the Company’s 6% Series C Convertible Cumulative Preferred Stock are described in greater detail in the April 23, 2024 Current Report on Form 8-K.

Item5.08. Shareholder Director Nominations.

The information in Item 8.01 of this Current Report on Form 8-K under “2024 Annual Meeting”, is incorporated by reference into this Item 5.08, to the extent applicable.

Item8.01 Other Events.

RisksRelated to our Common Stock

The Company is including the below update to its risk factors, for the purpose of supplementing and updating the disclosure contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on April 1, 2024.

Ifwe fail to comply with the continued minimum closing bid requirements of The Nasdaq Capital Market by October 24, 2024, or other requirementsfor continued listing, including stockholder equity requirements, our common stock may be delisted and the price of our common stockand our ability to access the capital markets could be negatively impacted.

Our common stock is listed for trading on Nasdaq. In order to remain listed on Nasdaq, we must satisfy Nasdaq’s continued listing requirements, including, among other things, the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

On October 30, 2023, the Staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Staff”) notified us that we did not comply with the Minimum Bid Price Requirement, and that we had 180 calendar days, or until April 29, 2024, to regain compliance. On April 25, 2024, under the Nasdaq Listing Rules, we submitted a request to Nasdaq for an additional 180-day extension to regain compliance with the Minimum Bid Price Requirement and notice of our intention to cure the deficiency, including by effecting a reverse stock split if necessary. On April 30, 2024, Nasdaq advised us that we were provided an additional 180 calendar day compliance period, or until October 24, 2024, to regain compliance with the Minimum Bid Price Requirement. The closing bid price of our securities must be at least $1.00 per share for a minimum of ten consecutive business days to regain compliance. We intend to monitor the closing bid price of our common stock and plan, if necessary, to implement a reverse stock split, to regain compliance with the Minimum Bid Price Requirement. The stockholders of the Company, at the March 25, 2024, special meeting of stockholders previously approved an amendment to our Certificate of Formation, as amended, to effect a reverse stock split of our issued and outstanding shares of our common stock, by a ratio of between one-for-two to one-for-fifty, inclusive, with the exact ratio to be set at a whole number to be determined by our Board of Directors or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and prior to March 25, 2025.

If we seek to implement a reverse stock split in order to remain listed on Nasdaq, the announcement or implementation of such a reverse stock split could negatively affect the price of our common stock. However, there can be no assurance that we will regain compliance with the Minimum Bid Price Requirement prior to October 24, 2024.

If we are unable to regain compliance with the Minimum Bid Price Requirement by October 24, 2024, or if we fail to meet any of the other continued listing requirements, including stockholder equity requirements (which we are required to meet as of the filing of our next periodic report with the Commission), our securities may be delisted from Nasdaq, which could reduce the liquidity of our common stock materially and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and business development opportunities. Such a delisting likely would impair your ability to sell or purchase our common stock when you wish to do so. Further, if we were to be delisted from Nasdaq, our common stock may no longer be recognized as a “covered security” and we would be subject to regulation in each state in which we offer our securities. Thus, delisting from Nasdaq could adversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantly impact the ability of investors to trade our securities and would negatively impact the value and liquidity of our common stock.

Ifwe implement a reverse stock split, the liquidity of our common stock may be adversely effected.

As discussed above, the stockholders of the Company, at the March 25, 2024 special meeting of stockholders, our stockholders approved an amendment to our Certificate of Formation, as amended, to effect a reverse stock split of our issued and outstanding shares of our common stock, by a ratio of between one-for-two to one-for-fifty, inclusive, with the exact ratio to be set at a whole number to be determined by our Board of Directors or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and prior to March 25, 2025. The Company plans to complete a reverse stock split within the stockholder approved ratio, if required to comply with the Nasdaq Minimum Bid Price Requirement, and if deemed to be in the interests of the Company. However, there can be no assurance that the market price per new share of our common stock after the reverse stock split will remain unchanged or increase in proportion to the reduction in the number of old shares of our common stock outstanding before the reverse stock split. The liquidity of the shares of our common stock may be affected adversely by any reverse stock split given the reduced number of shares of our common stock that will be outstanding following the reverse stock split, especially if the market price of our common stock does not increase as a result of the reverse stock split. In addition, the reverse stock split may increase the number of stockholders who own odd lots (less than 100 shares) of our common stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares and greater difficulty effecting such sales.

Following any reverse stock split, the resulting market price of our common stock may not attract new investors and may not satisfy the investing requirements of those investors. Although we believe that a higher market price of our common stock may help generate greater or broader investor interest, there can be no assurance that the reverse stock split will result in a share price that will attract new investors, including institutional investors. In addition, there can be no assurance that the market price of our common stock will satisfy the investing requirements of those investors. As a result, the trading liquidity of our common stock may not necessarily improve.

2024Annual Meeting

On May 1, 2024, the Board of Directors (the “Board”) of the Company determined that the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) will be held on June 17, 2024, subject to extension for any comments the Company may receive on the Annual Meeting Proxy. The time and location of the 2024 Annual Meeting will be set forth in the Company’s definitive proxy statement for the Annual Meeting to be filed with the Commission (the “Annual Meeting Proxy”).

Any stockholder proposal intended to be considered for inclusion in the Company’s proxy materials for the 2024 Annual Meeting in accordance with Rule 14a-8 or pursuant to the Company’s Bylaws (the “Bylaws”) must be delivered to, or mailed to and received at, the Company’s principal executive offices at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas, 75248, Attention: Corporate Secretary, on or before the close of business on May 13, 2024, which date the Company has determined to be a reasonable time before it expects to begin to print and distribute its proxy materials prior to the 2024 Annual Meeting. Additionally, any stockholder who intends to submit a director nomination or who intends to submit a proposal regarding any other matter of business at the 2024 Annual Meeting other than in accordance with Rule 14a-8 or otherwise must similarly make sure that such nomination or proposal is delivered to, or mailed and received at, the Company’s principal executive offices on or before the close of business on May 13, 2024.

In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the Company’s proxy materials for the 2024 Annual Meeting must also comply with all applicable Commission rules, including Rule 14a-8, Texas law and the Company’s Bylaws. Any proposal submitted after the above deadlines will be considered untimely and not properly brought before the 2024 Annual Meeting.

PressRelease

On May 2, 2024, the Company issued a press release announcing that the Company was granted a 180-day extension to meet Nasdaq Minimum Bid Price Requirement and conditional approval of compliance with Nasdaq’s minimum stockholders’ equity requirement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item9.01 Exhibits.

(d) Exhibits.

Exhibit No.	Description
3.1*	Certificate of Correction to Certificate of Designations, Preferences and Rights of 6% Series C Convertible Preferred Stock of Mangoceuticals, Inc., filed with the Secretary of State of Texas on April 29, 2024
99.1*	Mangoceuticals, Inc. Press Release dated May 2, 2024
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MANGOCEUTICALS, INC.
Date:<br> May 2, 2024	By:	/s/ Jacob D. Cohen
		Jacob<br> D. Cohen
		Chief<br> Executive Officer

Exhibit3.1

CERTIFICATEOF DESIGNATIONS

MANGOCEUTICALS,INC.

ESTABLISHINGTHE DESIGNATIONS, PREFERENCES,

LIMITATIONSAND RELATIVE RIGHTS OF ITS

6%SERIES C CONVERTIBLE CUMULATIVE PREFERRED STOCK

Pursuant to Section 21.155 of the Texas Business Organizations Code (the “TBOC”), Mangoceuticals, Inc., a corporation organized and existing under the TBOC (the “Company”),

DOESHEREBY CERTIFY that pursuant to the authority conferred upon the Board of Directors by the Certificate of Formation of the Company, as amended (the “Certificate of Formation”), and pursuant to Section 21.155 of the TBOC, the Board of Directors, pursuant to Section 6.201 of the TBOC, by unanimous consent of all members of the Board of Directors on April 18, 2024, duly adopted a resolution providing for the designation of a series of Six Million Two Hundred and Fifty Thousand (6,250,000) shares of Series C Convertible Preferred Stock, which resolution is and reads as follows:

RESOLVED, that pursuant to the authority expressly granted to and invested in the Board of Directors by the provisions of the Certificate of Formation of the Company and Section 21.155 of the TBOC, the Company hereby establishes a new series of Preferred Stock, par value $0.0001 per share, of the Company and fixes the number of shares of such series and the powers, designations, preferences and relative rights of such series, and the qualifications, limitations or restrictions thereof as follows:

The new series of Preferred Stock, par value $0.0001 per share, of the Company shall be, and hereby is, designated “6% SeriesC Convertible Cumulative Preferred Stock” (the “Series C Preferred Stock” or the “PreferredStock”), and the initial number of designated shares constituting such series shall be Six Million Two Hundred and Fifty Thousand (6,250,000) (the “Shares”). The powers and preferences, and the relative, participating, optional and other rights, and the qualifications, limitations, and restrictions thereon of the Series C Preferred Stock shall be set forth in this Certificate of Designations (the “Designation” or the “Certificate of Designation”) below:

1.Definitions. For purposes of the Shares and as used in this Designation, in addition to other terms defined throughout this Designation, the following terms have the following meanings when used herein:

“Board” shall mean the board of directors of the Company or any committee of members of the board of directors authorized by such board to perform any of its responsibilities with respect to the Shares.

“BusinessDay” shall mean any day other than a Saturday, Sunday or a day on which state or federally chartered banking institutions in New York, New York are not required to be open.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 1 |

| --- | --- |

“CallDate” shall mean the date fixed for redemption of the Shares and specified in the notice to Holders required under paragraph (b) of Section 4(b) hereof as the Call Date.

“ClosingSales Price” means the last sales price of the Company’s Common Stock on the Principal Market as reported by NASDAQ.com (or a comparable reporting service of national reputation)(collectively, “NASDAQ.com”), or if the foregoing does not apply, the last reported sales price of such security on a national exchange or in the over-the-counter market on the electronic bulletin board for such security as reported by NASDAQ.com, or, if no such price is reported for such security by NASDAQ.com, the average of the bid prices of all market makers for such security as reported in the “pink sheets” by OTC Markets, in each case for such date or, if such date was not a Trading Day for such security, on the next preceding date that was a Trading Day. If the Closing Sales Price cannot be calculated for such security as of either of such dates on any of the foregoing bases, the Closing Sales Price of such security on such date shall be the fair market value as reasonably determined by the Company.

“CommonShares” or “Common Stock” shall mean the shares of common stock, $0.0001 par value, of the Company.

“Company” shall mean Mangoceuticals, Inc., a Texas corporation.

“ConversionPrice” means $10.00, subject to adjustment in connection with any Recapitalization.

“ConversionRights” shall have the meaning set forth in Section 5 hereof.

“Designation” shall mean this Certificate of Designations of Mangoceuticals, Inc. Establishing the Designations, Preferences, Limitations and Relative Rights of Its 6% Series C Convertible Preferred Stock.

“DividendPayment Date” shall have the meaning set forth in subparagraph (a) of Section 2.3 hereof.

“DividendPeriods” shall mean quarterly dividend periods commencing on the first day of each of January, April, July and October and ending on and including the day preceding the first day of the next succeeding Dividend Period.

“DividendRate” is 6% per annum.

“ExchangeAct” shall mean the U.S. Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.

“IssueDate” shall mean the date that any Shares are first issued by the Company.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 2 |

| --- | --- |

“Holder” shall mean the person or entity in which the Shares are registered on the books of the Company, which shall initially be the person or entity which such Shares are issued to, and shall thereafter be permitted and legal assigns which the Company is notified of by the Holder and which the Holder has provided a valid legal opinion in connection therewith to the Company and to whom such Shares are legally transferred.

“JuniorShares” shall have the meaning set forth in paragraph (a)(iii) of Section 7(a)(iii) hereof.

“LiquidationPreference” means the Stated Value.

“ParityShares” shall have the meaning set forth in paragraph (a)(ii) of Section 7(a)(ii) hereof.

“Person” shall mean any individual, firm, partnership, limited liability company, corporation or other entity, and shall include any successor (by merger or otherwise) of such entity.

“PreferredStock Certificates” means the stock certificate(s) issued by the Company representing the applicable Series C Preferred Stock shares.

“PrincipalMarket” means initially the Nasdaq Capital Market and shall also include the New York Stock Exchange, NYSE American, the Nasdaq Global Market, the OTCQB, the OTCQX or the OTC Pink Market, whichever is at the time the principal trading exchange or market for the Common Shares, based upon share volume.

“Recapitalization” shall mean any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event described in Sections 10(b) through (c).

“RecordDate” shall have the meaning set forth in Section 2.2 hereof.

“RestrictedShares” means shares of the Company’s Common Stock which are restricted from being transferred by the Holder thereof unless the transfer is effected in compliance with the Securities Act and applicable state securities laws (including investment suitability standards, which shares shall bear the following restrictive legend (or one substantially similar)):

Thesecurities represented by this certificate have not been registered under the Securities Act of 1933 or any state securities act. Thesecurities have been acquired for investment and may not be sold, transferred, pledged or hypothecated unless (i) they shall have beenregistered under the Securities Act of 1933 and any applicable state securities act, or (ii) the corporation shall have been furnishedwith an opinion of counsel, satisfactory to counsel for the corporation, that registration is not required under any such acts.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 3 |

| --- | --- |

“SecuritiesAct” means the Securities Act of 1933, as amended (and any successor thereto) and the rules and regulations promulgated thereunder.

“SeniorShares” shall have the meaning set forth in paragraph (a)(i) of Section 7 hereof.

“setapart for payment” shall be deemed to include, without any further action, the following: the recording by the Company in its accounting ledgers of any accounting or bookkeeping entry that indicates, pursuant to an authorization by the Board and a declaration of dividends or other distribution by the Company, the initial and continued allocation of funds to be so paid on any series or class of shares of stock of the Company; provided, however, that if any funds for any class or series of Junior Shares or any class or series of Parity Shares are placed in a separate account of the Company or delivered to a disbursing, paying or other similar agent, then “setapart for payment” with respect to the Shares shall mean irrevocably placing such funds in a separate account or irrevocably delivering such funds to a disbursing, paying or other similar agent.

“Shares” has the meaning set forth in the introductory paragraphs hereof.

“SimpleMajority” means the holders of at least a majority of the then issued and outstanding Shares.

“StatedValue” means $20.00 per Share, as adjusted pursuant to Sections 2.5 and 2.6 hereof, as applicable.

“TradingDay” means any day on which the Common Shares are traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Shares, then on the principal securities exchange or securities market on which the Common Shares is then traded; provided that “Trading Day” shall not include any day on which the Common Shares is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Shares is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York Time).

“TransferAgent” means ClearTrust, LLC, or such other agent or agents of the Company as may be designated by the Board or its duly authorized designee as the transfer agent, registrar and dividend disbursing agent for the Shares, including, at the option of the Board, the Company itself.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 4 |

| --- | --- |

2. Dividends.

2.1 Dividends in General. From and after the Issue Date of each Share, each Share shall be entitled to receive, when, as and if authorized and declared by the Board of Directors, out of any funds legally available therefor, cumulative dividends in an amount equal to (i) the Dividend Rate on the Stated Value of such Share as of the Record Date for such dividend (each such dividend on the Shares, a “RegularDividend” and, collectively, the “Regular Dividends”), and (ii) on an as-converted basis, any dividend or other distribution, whether paid in cash, in-kind or in other property (including, for the avoidance of doubt, any securities other than Common Shares, but not in connection with any stock dividend paid solely in Common Shares), authorized and declared by the Board of Directors on the issued and outstanding Common Shares in an amount determined by assuming that the number of Common Shares into which such Share could be converted pursuant to Section 5 hereof, on the applicable Record Date for such dividend or distribution on the Common Shares were issued to, and held by, the Holder of such Share on such Record Date (each such dividend on the Shares pursuant to this clause (ii), a “Participating Dividend” and, collectively, the “Participating Dividends” and, together with the Regular Dividends, the “Dividends”).

2.2 “Record Date” shall mean, with respect to any dividend, distribution or other transaction or event in which the holders of Common Shares or shares of Shares, as applicable, have the right to receive any cash, securities or other property or in which the Common Shares or shares of Shares (or other applicable security), as applicable, are exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of shareholders entitled to receive such cash, securities or other property (whether such date is fixed by the Board of Directors or a committee thereof, or by statute, contract, this Certificate of Designations or otherwise). With respect to any Regular Dividend payable on any Regular Dividend Payment Date, the Record Date therefor will be the immediately preceding March 15, June 15, September 15 or December 15, as applicable.

2.3 Payment of Regular Dividends. Regular Dividends shall be payable quarterly in arrears, if, as and when authorized and declared by the Board of Directors, or any duly authorized committee thereof, to the extent not prohibited by law, on March 31, June 30, September 30 and December 31 of each year (unless any such day is not a Business Day, in which event such Regular Dividends shall be payable on the next succeeding Business Day, without accrual of interest thereon to the actual payment date), commencing on June 30, 2024 (each such payment date, a “Regular Dividend Payment Date,” and the period from, and including, the Issue Date to, and including, the first Regular Dividend Payment Date and each such quarterly period thereafter from, but excluding, the immediately preceding Regular Dividend Payment Date to, and including, the next occurring Regular Dividend Payment Date, a “Regular DividendPeriod”). The amount of Regular Dividends payable in respect of each Share for any period shall be computed on the basis of a 360-day year consisting of twelve thirty-day months. Regular Dividends shall begin to accrue from the Issue Date whether or not declared and whether or not the Company has assets legally available to make payment thereof, at a rate equal to the Dividend Rate and, if not declared and paid, shall be cumulative, regardless of whether or not in any Regular Dividend Period there are funds of the Company legally available for the payment of such Regular Dividend. In the event that the Board of Directors has authorized the payment of any Regular Dividend, the Company may, in its sole discretion and notwithstanding anything to the contrary in this Certificate of Designations, settle such Regular Dividend in cash out of funds legally available therefor, in Common Shares pursuant to the terms and conditions of Section 2.4, in-kind pursuant to the terms and conditions of Section 2.4, or a combination of cash and in-kind settlement pursuant to the terms and conditions of Section 2.6, and the Company shall set aside sufficient funds for the portion of any Regular Dividend to be paid in whole or in part in cash before the Board of Directors or any other authorized Person may declare, set apart funds for or pay any dividend on the Junior Shares; provided, however, that, to the extent any such payment in cash is prohibited by applicable law, such payment will be made in Common Shares in accordance with the terms and conditions of Section 2.4 or in-kind in accordance with the terms and conditions of Section 2.4. Participating Dividends shall be payable as and when paid to the holders of Common Shares (each such date, a “Participating Dividend Payment Date” and, together with a Regular Dividend Payment Date, a “Dividend Payment Date”). Participating Dividends are payable on a cumulative basis once declared, regardless of whether or not there are then funds of the Company available for the payment of such Participating Dividend pursuant to law.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 5 |

| --- | --- |

2.4 Dividends Paid in Common Shares. With respect to each Share, any Regular Dividend or portion thereof in respect of such Share that has accrued during any applicable Regular Dividend Period but is not paid (in whole or in part) in cash or by a PIK Dividend (pursuant to Section 2.5 hereof) on the applicable Regular Dividend Payment Date may be paid at the option of the Company in Common Shares, by issuing each Holder a number of Common Shares equal to (x) the total amount of the Regular Dividend due to such Holder, divided by (y) the Closing Sales Price, rounded up to the nearest whole Common Share (“Dividend Shares”). Dividend Shares shall be issued to each Holder within five (5) Trading Days of the applicable Divided Payment Date.

2.5 Accrued or PIK Dividends. With respect to each Share, any Regular Dividend or portion thereof in respect of such Share that has accrued during any applicable Regular Dividend Period but is not paid (in whole or in part) in cash or Common Shares (pursuant to Section 2.4 hereof) on the applicable Regular Dividend Payment Date (the amount of any accrued and unpaid Regular Dividend with respect to any Share for any Regular Dividend Period, regardless of whether such Regular Dividend is paid in cash or kind, the “AccruedDividend Amount” with respect to such Share for such Regular Dividend Period) shall, regardless of whether or not such Regular Dividend is authorized and declared by the Board of Directors, or whether the Company has assets legally available to make payment thereof, be added to the Stated Value of such Share immediately following the close of business on such Regular Dividend Payment Date. Any such addition of the Accrued Dividend Amount in respect of a Share to the Stated Value of such Share pursuant to this Section 2.4 is referred to herein as a “PIK Dividend.” The Accrued Dividend Amount in respect of any Regular Dividend Period that is not paid (in whole or in part) in cash or in Common Shares pursuant to Section 2.4, shall, without duplication of any prior PIK Dividends (if any) only be added to the Stated Value of such Share once. Regular Dividends with respect to each Share shall continue, from and after the date of each PIK Dividend, if any, to accrue in an amount per annum equal to the Dividend Rate of the Stated Value of such Share as of the relevant Record Date. Notwithstanding anything to the contrary in this Certificate of Designations, the Company will not be permitted to make any PIK Dividend election to the extent such election would violate the listing standards of the Principal Market; provided, however, that nothing herein will affect the compounding of any Regular Dividend that the Company does not pay in cash (which compounding will apply even if the Company is otherwise prohibited from electing to make any PIK Dividend pursuant to this sentence).

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 6 |

| --- | --- |

2.6 Cash and PIK Dividends. In the event that the Board of Directors has authorized and declared the payment of a Regular Dividend and the settlement of such Regular Dividend payment in part by payment of cash to each Holder of Shares and in part pursuant to a PIK Dividend (any such Regular Dividend, a “Cash and PIK Dividend”), the Company shall, on the applicable Regular Dividend Payment Date and in respect of each Share, (i) pay to the Holder thereof an amount of cash equal to the Cash and PIK Dividend Cash Settlement Amount in respect of such Share, and (ii) add to the Stated Value of such Share an amount equal to (A) the Accrued Dividend Amount with respect to such Share for the Regular Dividend Period ending on, and including, such Regular Dividend Payment Date, minus (B) the Cash and PIK Dividend Cash Settlement Amount in respect of such Share. If the Board of Directors declares a Cash and PIK Dividend, and any portion of the cash payment of such Cash and PIK Dividend per Share is not paid pursuant to the terms of this Section 2.6, then such portion shall be added to the Stated Value of such Share in accordance with the terms of this Section 2.6.

2.7 In the event that the Board of Directors has authorized and declared the payment of a Participating Dividend, such Participating Dividend shall be paid in a manner consistent with the payments of dividends on the Common Shares. The Company will not declare any dividend or distribution on the Common Shares unless, concurrently therewith, the Company declares a corresponding Participating Dividend, except for dividends paid on Common Shares solely in Common Shares, which shall not be deemed Participating Dividends.

2.8 Partial Dividend Payments. Except as otherwise provided herein, if at any time the Company pays, in cash, less than the total amount of Dividends then accrued, but unpaid, with respect to the Shares, such cash payment shall be distributed pro rata among the Holders thereof based upon the Stated Value of all Shares held by each such Holder as of the Record Date for such payment. When Dividends are not paid in full upon the Shares, all dividends declared on Shares and any other class or series of stock which has parity rights with the Shares (“Parity Stock”) shall be paid pro rata so that the amount of dividends so declared on the Shares and each such other class or series of Parity Stock shall in all cases bear to each other the same ratio as accrued, but unpaid, Dividends (for the full amount of dividends that would be payable for the most recently completed Regular Dividend Period if dividends were declared in full on non-cumulative Parity Stock) on the Shares and such other class or series of Parity Stock bear to each other.

2.9 No dividend on the Shares will be declared by the Company or paid or set apart for payment by the Company in cash at such time as the terms and provisions of Senior Shares or any agreement of the Company, including any agreement relating to its indebtedness, prohibit such declaration, payment or setting apart for payment or provide that such declaration, payment or setting apart for payment would constitute a breach thereof or a default thereunder, or if such declaration, payment or setting aside of funds is restricted or prohibited under Texas law or other applicable law; provided, however, notwithstanding anything to the contrary contained herein, dividends on the Shares shall continue to accrue without interest and accumulate regardless of whether: (i) any or all of the foregoing restrictions exist; (ii) the Company has earnings or profits; (iii) there are funds legally available for the payment of such dividends; or (iv) such dividends are authorized by the Board. Accrued and unpaid dividends on the Shares will accumulate as of the Dividend Payment Date on which they first become payable or on the date of redemption of the Shares, as the case may be. Notwithstanding anything in this Section 2.9, no Dividends shall be paid on the Shares prior to the payment in full of all dividends due on Senior Shares.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 7 |

| --- | --- |

2.10 Within one Business Day of the Record Date for any Regular Dividend, the Company will send written notice to each Holder of shares of Shares stating (i) whether such Regular Dividend will be paid in cash, in Common Shares pursuant to Section 2.4 hereof, by increasing the Stated Value of each Share pursuant to Section 2.4, or pursuant to a Cash and PIK Dividend pursuant to Section 2.6, and (ii) if such Regular Dividend will be paid, at least in part, by increasing the Stated Value of a Share pursuant to Section 2.4 or pursuant to a Cash and PIK Dividend pursuant to Section 2.6, the Stated Value of each Share immediately before and immediately after the applicable increase. If the Company fails to send such written notice at or before the Close of Business on the Business Day immediately following the Record Date for any Regular Dividend, then the Company will be deemed to have irrevocably elected to pay such Regular Dividend by increasing the Stated Value of each Share pursuant to Section 2.4.

2.11 Non-Cash Distributions. Whenever a Participating Dividend shall be payable in property other than cash, the value of such Participating Dividend shall be deemed to be the fair market value of such property as determined in good faith by the Board of Directors.

2.12 Restricted Securities. Unless the Dividend Shares are covered by a valid and effective registration under the Securities Act or the Holder provides the Company a valid opinion from an attorney stating that such Dividend Shares can be issued free of restrictive legend, which shall be determined by the Company (or the Transfer Agent) in its sole discretion, such shares shall be issued as Restricted Shares.

3. Liquidation Preference.

(a) Subject to the priority rights of the holders of Senior Shares and the rights of the Parity Shares, in the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, after the payment in full of all amounts due to the holders of Senior Shares, but before any payment or distribution of the assets of the Company (whether capital or surplus) shall be made to or set apart for the holders of Junior Shares as to the distribution of assets on any liquidation, dissolution or winding up of the Company, each Holder of the Shares shall be entitled to receive an amount of cash equal to the Liquidation Preference. If, upon any liquidation, dissolution or winding up of the Company, after the payment in full to all holders of the Senior Shares, the assets of the Company, or proceeds thereof, distributable among the Holders of the Shares shall be insufficient to pay in full the preferential amount aforesaid and liquidating payments on any other shares of any class or series of Parity Shares as to the distribution of assets on any liquidation, dissolution or winding up of the Company, then such assets, or the proceeds thereof, shall be distributed among the Holders of Shares and any such other Parity Shares ratably in accordance with the respective amounts that would be payable on such Shares and any such other Parity Shares if all amounts payable thereon were paid in full.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 8 |

| --- | --- |

(b) Written notice of any such liquidation, dissolution or winding up of the Company, stating the payment date or dates when, and the place or places where, the amounts distributable in such circumstances shall be payable, shall be given by first class mail, postage pre-paid, not less than twenty (20) nor more than sixty (60) days prior to the payment date stated therein, to each record Holder of Shares at the respective address of such Holders as the same shall appear on the stock transfer records of the Company.

(c) Subject to the rights of the holders of Senior Shares and Parity Shares upon liquidation, dissolution or winding up, upon any liquidation, dissolution or winding up of the Company, after payment shall have been made in full to the Holders of the Shares, as provided in this Section 3, any other series or class or classes of Junior Shares shall, subject to the respective terms and provisions (if any) applying thereto, be entitled to receive any and all assets remaining to be paid or distributed, and the Holders of the Shares shall not be entitled to share therein.

(d) If any assets of the Company distributed to stockholders in connection with any liquidation, dissolution, or winding up of the Company are other than cash, then the value of such assets shall be their fair market value as determined in good faith by the Board of Directors.

4. Company Call Option.

(a) Optional Redemption at Election of Company. The Company may redeem the Shares, from time to time, in whole or in part, at any time after the first anniversary of the Issue Date and continuing indefinitely thereafter, at the option of the Company, for cash, at the aggregate Liquidation Preference of the Shares redeemed (the “Redemption Amount”). If fewer than all of the outstanding Shares are to be redeemed pursuant to the Company’s exercise of its redemption right under this Section 4(a), the Shares to be redeemed shall be selected pro rata (as nearly as practicable without creating fractional shares) or by lot or in such other equitable method prescribed by the Company.

(b) Redemption Procedures. Notice of the redemption of any Shares under paragraph (a) of this Section 4 shall be mailed by first class mail or via electronic mail to each Holder of record of Shares to be redeemed at the address of each such Holder as shown on the Company’s records, not less than twenty (20) nor more than sixty (60) days prior to the Call Date. Neither the failure to deliver any notice required by this paragraph (b), nor any defect therein or in the delivery thereof, to any particular Holder, shall affect the sufficiency of the notice or the validity of the proceedings for redemption with respect to the other Holders. Any notice delivered in the manner herein provided shall be conclusively presumed to have been duly given on the date mailed whether or not the Holder receives the notice. Each such mailed notice shall state, as appropriate: (1) the Call Date; (2) the number of Shares to be redeemed and, if fewer than all the Shares held by such Holder are to be redeemed, the number of such Shares to be redeemed from such Holder; (3) the redemption price per Share (determined as set forth in paragraph (a) of this Section 4); (4) if any Shares are represented by certificates, the place or places at which certificates for such Shares are to be surrendered; and (5) any other information required by law or by the applicable rules of any exchange or national securities market upon which the Shares may be listed or admitted for trading. Notice having been delivered as aforesaid, from and after the Call Date (unless the Company shall fail to make available an amount of cash necessary to effect such redemption), (i) said Shares shall no longer be deemed to be outstanding, and (ii) all rights of the Holders thereof as Holders of Shares shall cease (except the right to receive cash payable upon such redemption, without interest thereon, upon surrender and endorsement of their certificates if so required).

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 9 |

| --- | --- |

(c) Set Asides. The Company’s obligation to provide cash in accordance with the preceding subsection shall be deemed fulfilled if, on or before the Call Date, the Company shall irrevocably deposit funds necessary for such redemption, in trust, with a bank or trust company that has, or is an affiliate of a bank or trust company that has, capital and surplus of at least $50 million, with irrevocable instructions that such cash be applied to the redemption of the Shares so called for redemption, in which case the notice to Holders of the Shares will (i) state the date of such deposit, (ii) specify the office of such bank or trust company as the place of payment of the redemption price and (iii) require such Holders to surrender the certificates, if any, representing such Shares at such place on or about the date fixed in such redemption notice (which may not be later than the Call Date) against payment of the redemption price. No interest shall accrue for the benefit of the Holders of Shares to be redeemed on any cash so set aside by the Company. Subject to applicable escheat laws, any such cash unclaimed at the end of six months from the Call Date shall revert to the general funds of the Company after which reversion the Holders of such Shares so called for redemption shall look only to the general funds of the Company for the payment of such cash.

(d) Holder Obligations. Without limiting the obligation of each Holder set forth herein (including in the subsequent clause (e)), the Company and/or the Company’s Transfer Agent shall be authorized to take whatever action necessary, if any, following the issuance and delivery of the Redemption Amount to reflect the cancellation of the Series C Preferred Stock subject to the redemption, which shall not require the approval and/or consent of any Holder (a “Cancellation”).

(e) Further Assurances. Notwithstanding the above, each Holder, by accepting such Preferred Stock certificates (if any) hereby covenants that it will, whenever and as reasonably requested by the Company and the Transfer Agent, at the Company’s sole cost and expense, do, execute, acknowledge and deliver any and all such other and further acts, deeds, assignments, transfers, conveyances, confirmations, powers of attorney and any instruments of further assurance, approvals and consents as the Company or the Transfer Agent may reasonably require in order to complete, insure and perfect the Cancellation, if such may be reasonably required by the Company and/or the Company’s Transfer Agent.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 10 |

| --- | --- |

5.Conversion. The Holders of the Shares shall have conversion rights as follows (the “ConversionRights”):

(a) Right to Convert. Each Share shall be convertible (each a “Conversion”) into that number of fully-paid, nonassessable Common Shares determined by dividing (i) the Stated Value, by (ii) the Conversion Price (such total number of Common Shares due, the “Conversion Shares”), at the option of the Holder thereof, in whole or in part at any time after the second anniversary of the Issue Date and continuing indefinitely thereafter, at the option of the Holder, by providing a notice in the form attached hereto, to the Company, at the office of the Company or any transfer agent for such stock. If any conversion of Series C Preferred Stock would result in the issuance of a fractional number of Common Shares (aggregating all shares of Series C Preferred Stock being converted), then, the number of shares of Common Shares issuable upon conversion of the Series C Preferred Stock shall be the next higher whole number of shares.

(b) Mechanics of Conversion. Before any Holder of Shares shall be entitled to convert the same into Common Shares, they shall surrender the certificate or certificates therefor, duly endorsed, at the office of this Company or of any transfer agent for the Shares, and shall give written notice to this Company at its principal corporate office, of the election to convert the same and shall state therein the name or names in which the certificate or certificates for Common Shares are to be issued. This Company shall, as soon as practicable thereafter, issue and deliver at such office to such Holder of Shares, or to the nominee or nominees of such Holder, a certificate or certificates for the number of Common Shares to which such Holder shall be entitled as aforesaid. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the Shares to be converted, and the person or persons entitled to receive the Common Shares issuable upon such conversion shall be treated for all purposes as the record Holder or Holders of such Common Shares as of such date.

(c) No Impairment. The Company will not, by amendment of its Certificate of Formation or through any reorganization, recapitalization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by this Company, but will at all times in good faith assist in the carrying out of all the provisions of this Section and in the taking of all such action as may be necessary or appropriate in order to protect the Conversion Rights of the Holders of the Shares against impairment.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 11 |

| --- | --- |

(d) Notice. Any notice required by the provisions of this Section to be given to the Holders of Shares shall be deemed given if deposited in the United States mail, postage prepaid, and addressed to each Holder of record at his address appearing on the books of the Company.

(e) Restricted Shares. Unless the Conversion Shares are covered by a valid and effective registration under the Securities Act or the Holder provides the Company a valid opinion from an attorney stating that such Conversion Shares can be issued free of restrictive legend, which shall be determined by the Company (or the Transfer Agent) in its sole discretion, such shares shall be issued as Restricted Shares.

(f) Beneficial Ownership Limitation for Conversion; Exchange Cap.

(i) No Holder Conversion shall result in the conversion of more than that number of shares of Series C Preferred Stock, if any, such that, upon such Conversion, the aggregate beneficial ownership of the Company’s Common Shares (calculated pursuant to Rule 13d-3 of the Exchange Act) of such Holder and all persons affiliated with such Holder as described in Rule 13d-3 is more than 4.999% of the Company’s Common Shares then outstanding (the “Maximum Percentage”). By written notice to the Company, a Holder may increase or decrease the Maximum Percentage to any percentage not in excess of 9.999% as specified in such written notice; provided that (A) any such increase will not be effective until the 61st day after such notice is received by the Company; and (B) any such increase or decrease will apply only to the requesting Holder and not to any other Holder. In the event any Conversion would result in the issuance of shares of Common Shares to any Holder in excess of the Maximum Percentage, only that number of shares of Series C Preferred Stock which when Converted would not result in such Holder exceeding the Maximum Percentage shall be subject to such applicable Conversion, if any, and Holder shall continue to hold any remaining shares of Series C Convertible Preferred Stock, the conversion of which would result in Holder exceeding the Maximum Percentage.

(ii) The Company’s Transfer Agent shall be authorized to promptly disclose the total outstanding Common Shares to the Holder from time to time at the request of the Holder in order for the Holder to determine its compliance with the Maximum Percentage.

(iii) The Company shall not be required to verify or investigate or confirm whether any Conversion would exceed the Maximum Percentage, and instead the Company shall be able to rely on any notice of holder conversion as prima facie evidence of, and as a representation by, the applicable Holder, that such applicable conversion described in the notice of holder conversion would not result in a violation of the Maximum Percentage.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 12 |

| --- | --- |

(iv) The Maximum Percentage shall not apply to any Common Shares issued by the Company in connection with a redemption as described in Section 4 hereof.

(v) Until the Company obtains approval to waive this Section 5(f)(v) by the requisite number of its stockholders at a duly called special or annual meeting of stockholders, the Company shall not deliver Common Shares, Dividend Shares, and/or upon Conversion Shares under Section 5 hereof, to the extent that (A) the aggregate Common Shares issued by the Company to all Holders pursuant to Section 2.4 as Dividend Shares, (B) the aggregate Common Shares issued by the Company to all Holders pursuant to Section 5, as Conversion Shares, plus (C) the aggregate Common Shares issued by the Company hereunder would exceed 19.99% of the Common Shares issued and outstanding on the date of this Designation, subject to adjustment in connection with any Recapitalization. No Holder shall vote any Common Shares in favor of any proposal to waive this Section 5(f)(v) at any meeting of Common Stockholders.

6. Status of Acquired Shares. All Shares issued, redeemed by the Company or converted by the Holder in accordance with Sections 4 or 5 hereof, or otherwise acquired by the Company, shall be cancelled by the Company.

7. Ranking.

(a) Any class or series of shares of stock of the Company that shall be deemed to rank:

(i) prior to the Shares, as to the payment of dividends and as to distribution of assets upon liquidation, dissolution or winding up, if the Holders of such class or series shall be entitled to the receipt of dividends or of amounts distributable upon liquidation, dissolution or winding up, as the case may be, in preference or priority to the Holders of Shares, and such shares shall be defined as “SeniorShares”. For the sake of clarity and in an abundance of caution, the Series B Convertible Preferred Stock of the Company shall be deemed Senior Shares;

(ii) on a parity with the Shares, as to the payment of dividends and as to distribution of assets upon liquidation, dissolution or winding up, whether or not the dividend rates, dividend payment dates or redemption or liquidation prices per share thereof be different from those of the Shares, if the Holders of such class or series and the Shares shall be entitled to the receipt of dividends and of amounts distributable upon liquidation, dissolution or winding up in proportion to their respective amounts of accrued and unpaid dividends per share or liquidation preferences, without preference or priority one over the other (“Parity Shares”); and

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 13 |

| --- | --- |

(iii) junior to the Shares, as to the payment of dividends and as to the distribution of assets upon liquidation, dissolution or winding up, if such class or series shall be the Common Shares or any other class or series of shares of stock of the Company now or hereafter issued and outstanding over which the Shares have preference or priority in the payment of dividends and in the distribution of assets upon any liquidation, dissolution or winding up of the Company (“Junior Shares”).

(b) The Company’s Common Shares shall be considered Junior Shares relative to the Shares.

8.Voting Rights. Except for the Protective Provisions described below, and as expressly required by the NRS, the Series C Preferred Stock shall not have any voting rights. For so long as any Shares are outstanding, the Company shall not, without first obtaining the approval (at a meeting duly called or by written consent, as provided by law) of a Simple Majority (collectively, the “ProtectiveProvisions”):

(a) Amend any provision of this Designation;

(b) Increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series C Preferred Stock of the Company;

(c) Amend the Certificate of Formation of the Company (including by designating additional series of Preferred Stock) in a manner which adversely affects the rights, preferences and privileges of the Series C Convertible Preferred Stock;

(d) Effect an exchange, or create a right of exchange, cancel, or create a right to cancel, of all or any part of the shares of another class of shares into shares of Series C Preferred Stock; or

(e) Alter or change the rights, preferences or privileges of the shares of Series C Preferred Stock so as to affect adversely the shares of such series.

Except as required by applicable provisions of Texas law, the Shares shall not have any relative, participating, optional or other special voting rights and powers other than as set forth herein, and the consent of the Holders thereof shall not be required for the taking of any corporate action. No amendment to these terms of the Shares shall require the vote of the holders of Common Shares (except as required by law).

9. Record Holders. The Company and the Transfer Agent shall deem and treat the record Holder of any Shares as the true and lawful owner thereof for all purposes, and neither the Company nor the Transfer Agent shall be affected by any notice to the contrary.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 14 |

| --- | --- |

10. Adjustments for Recapitalizations.

(a) Equitable Adjustments for Recapitalizations. (i) The Liquidation Preference, the Stated Value, and the Conversion Price, and any provisions hereof which are expressly tied to the price or value of Shares (each, as and if applicable) (the “Preferred StockAdjustable Provisions”), and; (ii) any and all other terms, conditions, amounts and provisions of this Designation which (x) pursuant to the terms of this Designation provide for equitable adjustment in the event of a Recapitalization (the “OtherEquitable Adjustable Provisions”); or (y) the Board of Directors of the Company determines in their reasonable good faith judgment is required to be equitably adjusted in connection with any Recapitalizations, shall each be subject to equitable adjustment as provided in Sections 10(b) through (c), below, as determined by the Board of Directors in their sole and reasonable discretion.

(b) Adjustments for Subdivisions or Combinations of Common Shares. In the event the outstanding Common Shares shall be subdivided (by stock split, by payment of a stock dividend or otherwise), into a greater number of Common Shares, without a corresponding subdivision of the Series C Preferred Stock and the Other Equitable Adjustable Provisions (if any) in effect immediately prior to such subdivision shall, concurrently with the effectiveness of such subdivision, be proportionately and equitably adjusted. In the event the outstanding Common Shares shall be combined (by reclassification or otherwise) into a lesser number of shares of Common Stock, without a corresponding combination of the Series C Preferred Stock and the Other Equitable Adjustable Provisions (if any) in effect immediately prior to such combination shall, concurrently with the effectiveness of such combination, be proportionately and equitably adjusted.

(c) Adjustments for Subdivisions or Combinations of Series C Preferred Stock. In the event the outstanding shares of Series C Preferred Stock shall be subdivided (by stock split, by payment of a stock dividend or otherwise), into a greater number of shares of Series C Preferred Stock, the applicable Preferred Stock Adjustable Provisions and the Other Equitable Adjustable Provisions (if any) in effect immediately prior to such subdivision shall, concurrently with the effectiveness of such subdivision, be proportionately and equitably adjusted. In the event the outstanding shares of Series C Preferred Stock shall be combined (by reclassification or otherwise) into a lesser number of shares of Series C Preferred Stock, the applicable Preferred Stock Adjustable Provisions and the Other Equitable Adjustable Provisions (if any) in effect immediately prior to such combination shall, concurrently with the effectiveness of such combination, be proportionately and equitably adjusted. Provided however that the result of any concurrent adjustment in the Common Shares (as provided under Section 10(b)) and Series C Preferred Stock (as provided under Section 10(c)) shall only be to affect the equitable adjustable provisions hereof once.

(d) Other Adjustments. The Board of Directors of the Company shall also adjust equitably, and shall have the right to adjust equitably, any or all of the Preferred Stock Adjustable Provisions or Other Equitable Adjustable Provisions from time to time, if the Board of Directors of the Company determines in their reasonable good faith judgment that such values and/or provisions are required to be equitably adjusted in connection with any Company action.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 15 |

| --- | --- |

(f) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 10, the Company at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based. The Company shall, upon the reasonable written request at any time of any Holder, furnish or cause to be furnished to such Holder a like certificate setting forth (i) such adjustments and readjustments, (ii) the Conversion Price at the time in effect, and (iii) the number of Common Shares and the amount, if any, of other property which at the time would be received upon the conversion of the Series C Preferred Stock.

11.Sinking Fund. The Shares shall not be entitled to the benefits of any retirement or sinking fund.

12.Uncertificated Book-Entry Securities. At the option of the Company, the Shares may be issued as book-entry securities directly registered in the stockholder’s name on the Company’s or Transfer Agent’s books and records. If entered as book-entry, the Shares need not be represented by certificates, but instead would be uncertificated securities of the Company.

13.Other Rights. Except as otherwise stated herein, there are no other rights, privileges, or preferences attendant or relating to in any way to the Shares, including by way of illustration but not limitation, those concerning participation, or anti-dilution rights or preferences.

14.Reports. The Company shall mail to all Holders of Series C Preferred Stock those reports, proxy statements and other materials that it mails to all of its Holders of Common Shares.

15. ReplacementPreferred Stock Certificates. In the event that any Holder notifies the Company that a Preferred Stock Certificate evidencing shares of Series C Preferred Stock has been lost, stolen, destroyed or mutilated, the Company shall issue a replacement stock certificate evidencing the Series C Preferred Stock identical in tenor and date (or if such certificate is being issued for shares not covered in a redemption or conversion, in the applicable tenor and date) to the original Preferred Stock Certificate evidencing the Series C Preferred Stock, provided that the Holder executes and delivers to the Company and/or its Transfer Agent, as applicable, an affidavit of lost stock certificate and an agreement reasonably satisfactory to the Company and its Transfer Agent to indemnify the Company from any loss incurred by it in connection with such Series C Preferred Stock certificate, and provides the Company and/or its Transfer Agent such other information, documents and if applicable, bonds and indemnities as the Company or its Transfer Agent customarily requires for reissuances of stock certificates (collectively the “Lost CertificateMaterials”); provided, however, the Company shall not be obligated to re-issue replacement stock certificates if the Holder contemporaneously requests the Company to convert or redeem the full number of shares evidenced by such lost, stolen, destroyed or mutilated certificate.

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 16 |

| --- | --- |

16.Construction. When used in this Designation, unless a contrary intention appears: (i) a term has the meaning assigned to it; (ii) “or” is not exclusive; (iii) “including” means including without limitation; (iv) words in the singular include the plural and words in the plural include the singular, and words importing the masculine gender include the feminine and neuter genders; (v) any agreement, instrument or statute defined or referred to herein or in any instrument or certificate delivered in connection herewith means such agreement, instrument or statute as from time to time amended, modified or supplemented and includes (in the case of agreements or instruments) references to all attachments thereto and instruments incorporated therein; (vi) the words “hereof”, “herein” and “hereunder” and words of similar import when used in this Designation shall refer to this Designation as a whole and not to any particular provision hereof; (vii) references contained herein to Article, Section, Schedule and Exhibit, as applicable, are references to Articles, Sections, Schedules and Exhibits in this Designation unless otherwise specified; (viii) references to “dollars”, “Dollars” or “$” in this Designation shall mean United States dollars; (ix) reference to a particular statute, regulation or law means such statute, regulation or law as amended or otherwise modified from time to time; (x) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (xi) unless otherwise stated in this Designation, in the computation of a period of time from a specified date to a later specified date, the word “from” means “from and including” and the words “to” and “until” each mean “to but excluding”; (xii) references to “days” shall mean calendar days; and (xiii) the paragraph and Section headings contained in this Designation are for convenience only, and shall in no manner affect the interpretation of any of the provisions of this Designation.

NOWTHEREFORE BE IT RESOLVED, that the Designation is hereby approved, affirmed, confirmed, and ratified; and it is further

RESOLVED, that each officer of the Company be and hereby is authorized, empowered and directed to execute and deliver, in the name of and on behalf of the Company, any and all documents, and to perform any and all acts necessary to reflect the Board of Directors approval and ratification of the resolutions set forth above; and it is further

RESOLVED, that in addition to and without limiting the foregoing, each officer of the Company and the Company’s attorney be and hereby is authorized to take, or cause to be taken, such further action, and to execute and deliver, or cause to be delivered, for and in the name and on behalf of the Company, all such instruments and documents as he may deem appropriate in order to effect the purpose or intent of the foregoing resolutions (as conclusively evidenced by the taking of such action or the execution and delivery of such instruments, as the case may be) and all action heretofore taken by such officer in connection with the subject of the foregoing recitals and resolutions be, and it hereby is approved, ratified and confirmed in all respects as the act and deed of the Company; and it is further

RESOLVED, that this Designation may be executed in several counterparts, each of which is an original; that it shall not be necessary in making proof of this Designation or any counterpart hereof to produce or account for any of the other.

[Remainder of page left intentionally blank. Signature page follows.]

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 17 |

| --- | --- |

IN WITNESS WHEREOF, Mangoceuticals, Inc. has approved and caused this “Certificate of Designation of Mangoceuticals, Inc. Establishing the Designations, Preferences, Limitations and Relative Rights of Its 6% Series C Convertible Preferred Stock” to be duly executed and approved this 18^th^ day of April 2024.

/s/ Jacob D. Cohen
Jacob D. Cohen
Chief<br> Executive Officer

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 18 |

| --- | --- |

NOTICEOF CONVERSION(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERTPREFERRED SHARES)

The undersigned hereby elects to convert the number of 6% Series C Convertible Preferred Shares indicated below into common shares, $0.0001 par value (the “Common Shares”), of Mangoceuticals Inc. (the “Company”), a corporation organized under the laws of the State of Texas, according to the conditions hereof, as of the date written below.

Conversion calculations:

Date to Effect Conversion:

Number<br> of Preferred Shares owned prior to Conversion:
Number<br> of Preferred Shares to be Converted:
Stated<br> Value of the Preferred Shares to be Converted:
Number<br> of Common Shares to be Issued:
Applicable<br> Conversion Price:

Number of Preferred Shares subsequent to Conversion:

_________________

Address<br> for Delivery:

DWAC Instructions:

Broker no:__________

Account no:__________

HOLDER
By:
	Name:
	Title:

| Mangoceuticals, Inc.: Certificate of Designations of 6% Series C Convertible Preferred Stock | Page 19 |

| --- | --- |

Exhibit99.1

MangoceuticalsGranted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s MinimumStockholders’ Equity Requirement

Dallas, Texas / May 2, 2024 / Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies, today announced that the Company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company now has until October 24, 2024 to meet the requirement. On the same date, Nasdaq provided notice to the Company that based on the Company’s April 25, 2024, Current Report on Form 8-K filing, Nasdaq has determined that the Company complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) which requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. However, Nasdaq also advised that if the Company fails to evidence compliance with the Rule upon filing its next periodic report it may be subject to delisting.

The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rule 5550(a)(2) on November 1, 2023, and was given until April 29, 2024, to regain compliance. At any time during the additional 180-day extension, if the bid price of the Company’s common stock closes at, or above, $1.00 per share for a minimum of ten consecutive business days, the Nasdaq staff will provide the Company with a written confirmation of compliance and the matter will be closed.

If the Company does not regain compliance within the allotted compliance period, and/or if the Company does not demonstrate compliance with the Rule as of the filing of its next periodic report, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the minimum bid price requirement during this 180-day extension.

On May 1, 2024, the Board of Directors of the Company determined that the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) will be held on June 17, 2024, subject to extension for any comments the Company may receive on the Annual Meeting Proxy. The time and location of the 2024 Annual Meeting will be set forth in the Company’s definitive proxy statement for the Annual Meeting to be filed with the Commission (the “Annual Meeting Proxy”).

AboutMangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

CautionaryNote Regarding Forward-Looking Statements

Certainstatements made in this press release contain forward-looking information within the meaning of applicable securities laws, includingwithin the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-lookingstatements represent the Company’s current expectations or beliefs concerning future events and can generally be identified usingstatements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,”“intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target”or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which areoutside of the Company’s control which could cause actual results to differ materially from the results expressed or implied inthe forward-looking statements, our ability to meet Nasdaq’s minimum bid price requirement; the Company’s stockholders’equity as of the Company’s next fiscal quarter end; our ability to maintain the listing of our common stock on Nasdaq; our abilityto commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitariosfor our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generaterevenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Foodand Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeksto prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our plannedproducts does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided bySection 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious codeand/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changesand/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls andlitigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings andcompete against competitors which may have greater resources; our significant reliance on related party transactions; the projected sizeof the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, JacobD. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, ourshare volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholderspaid less for their shares than the public offering price of our common stock in our recent initial public offering; dilution causedby recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we havea significant number of outstanding warrants to purchase shares of common stock at $1.00 per share, the resale of which underlying shareshave been registered under the Securities Act of 1933, as amended; our ability to build and maintain our brand; cybersecurity, informationsystems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations,sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connectionwith our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product;our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our MangoED product, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing ratesof inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, healthand industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scalecrises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively;overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentimentand economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potentialrecessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested bythe forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectationswill be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

Moreinformation on potential factors that could affect the Company’s financial results is included from time to time in the “CautionaryNote Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis ofFinancial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’sAnnual Report on Form 10-K for the year ended December 31, 2023. These filings are available at www.sec.gov and at our websiteat https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to theCompany or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referencedabove. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-lookingstatements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels ofactivity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally,the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takesno obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or moreforward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-lookingstatements.

FollowMangoceuticals and MangoRx on social media:

https://www.instagram.com/mango.rx

https://twitter.com/Mangoceuticals

https://www.facebook.com/MangoRxOfficial

FORPUBLIC RELATIONS

Lucky Break Public Relations

Sahra Simpson

Sahra@luckybreakpr.com

(323) 602-0091 ext. 704

FORINVESTOR RELATIONS

Mangoceuticals Investor Relations

Email: investors@mangorx.com

**SOURCE:**Mangoceuticals Inc.